Fusion Genomics is a Vancouver-based biotechnology company that is pushing the frontiers of molecular diagnostics with proprietary technologies, combined with Next Generation Sequencing, to create genomic testing for pathogens. Fusion Genomics is seeking to tackle the global problem of idiopathic infections, which cost the global economy billions of dollars in hospitalizations and lost productivity and exact a heavy human toll in hundreds of lost lives. Fusion Genomics’ disruptive DNA and RNA capture technology, part of a "benchtop to desktop solution" called the ONETestᵀᴹ platform enables the comprehensive identification of pathogens from virtually any source, including blood, sputum, stool, swabs, and cell free extracts, in eight to twelve hours. The platform uses Fusion Genomics proprietary UNIPrepᵀᴹ, QUANTUMProbesᵀᴹ, and FusionCloudᵀᴹ technologies and offers 10,000x the sensitivity, accuracy across 20% genetics distance, and at one-tenth the cost. The ONETestᵀᴹ platform has been validated by international laboratories working on behalf of the European Union and various Canadian public health agencies. For more information about Fusion Genomics diagnostic technologies or to explore investor opportunities, please contact: info@fusiongenomics.com
